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Rosmarinic acid is commonly found in species of the Boraginaceae and the subfamily Nepetoideae (Lamiaceae).I th a san u m b e r
ofinteresting biological activities, for example, antiviral, antibacterial, anti-inﬂammatory,and antioxidant.The aim of the present
study was to investigate the eﬀect of the i.p. administration of caﬀeic and rosmarinic acid (5 and 10mg/kg) on anti-inﬂammatory
and nociceptive response using carrageenan-induced pleurisy model and tail-ﬂick assay in rats. The analysis of cells in the pleural
exudates revealed a reduction of 66% of the number of leukocytes that migrated to the pleural cavity in the animals treated with
5mg/kgcaﬀeic acid, and of 92.9% for the animals treated with 10mg/kg in comparison with the control group. These exudates
showedabalanceddistribution ofpolymorphonuclear(PMN)andmononuclear(MN)cells,diﬀerently from the control group, in
which PMN cells were predominant. The analysisto tail-ﬂick latency was increased in the group treated with 10 mg/kg caﬀeic acid
characterizing a nociceptive response. While there was no diﬀerence between control group and animals treated with rosmarinic.
1.Introduction
Inﬂammation or phlogosis is a pathophysiological response
of mammalian tissues to a variety of hostile agents including
infectious organisms, toxic chemical substances, physical
injury, or tumor growth leading to local accumulation of
plasmic ﬂuid and blood cells [1].
Although inﬂammation is a defense mechanism, the
complex events and mediators involved in the inﬂammatory
reaction can induce, maintain, and aggravate many disor-
ders. This process is invariably characterized by the produc-
tion of prostaglandins, leukotrienes, histamine, bradykinin,
platelet-activating factor (PAF), and by the release of chem-
icals from tissues and migrating cells [2, 3]. It is well known
that the central feature of inﬂammatory activity is the
activation ofphagocyticcellsthatsynthesize and release large
amounts of reactive species, causing cell and tissue injury,
often directly by oxidative degradation of essential cellular
components [4].
Following tissue injury and inﬂammation, nociceptors
are sensitized, causing previously mild or ineﬀective stim-
ulation becomes painful [5]. In acute pain, nociceptive
transmission comprises a network of neuronal arrangement
distributed between peripheral, spinal, and supraspinal
levels. This occurs through the action of neurotransmitters,
neuromodulators, and intracellular messengers [6, 7].
Plants were historically the main source for obtain-
ing therapeutic agents. Natural selection and competition2 ISRN Pharmacology
among species led to the synthesis of secondary metabolites,
and many are used as drugs with marked biological activities
[8].
Rosmarinic acid is an ester of caﬀeic acid and 3,4-
dihydroxyphenyllactic acid. It is commonly found in Boragi-
naceaespeciesandin theNepetoideaesubfamilyoftheLami-
aceae.Itisalsofoundinspeciesofotherhigherplantfamilies,
and in some fern and hornwort species [9]. Rosmarinic acid
has a number of interesting biological activities, for example,
adstringent, antioxidative, antimutagen, antibacterial, and
antiviral eﬀects [10–16].
The anti-inﬂammatory properties of rosmarinic acid are
thought to be based on the inhibition of lipoxygenase and
cyclooxygenases, and on the interference of rosmarinic acid
with the complement cascade [9, 17–19] and the inhibition
of expression of inﬂammatory cytokines [20]. Caﬀeic acid
also inhibits 5-lipoxygenase (5-LOX) and protein kinase C
(PKC) activity [21, 22] besides antioxidant activity [23–26].
Therefore, the aim of this study was to investigate and
compare the eﬀects of rosmarinic and caﬀeic acids in vivo on
inﬂammatory and nociceptive processes using carrageenan-
induced pleurisy model and tail-ﬂick assay in rats.
2.Materialsand Methods
2.1. Animals. Male Wistar rats (12-week-old, weighing 200–
300g) from the animal unit of Universidade Feevale were
used in this study. All animals were housed at 25 ± 1◦C
with 12 hours light, 12 hours dark cycle and supplied with
standard rat chow and water freely available. Animals were
handled and cared according to NIH Guide for the Care
and Use of Laboratory Animals and the Brazilian Society for
Neuroscience and Behavior (SBNeC) recommendations for
animal care. This study was submitted to Ethical Committee
of Feevale and received approval by code no. 2.08.03.07.673.
2.2. Drugs and Pharmacological Procedure. Rosmarinic acid
and caﬀeic acid were purchased from Sigma Chemicals
(St. Louis, Mo., USA). Thirty minutes prior to procedures,
animals were pretreated. For pleurisy model, rats were
divided in ﬁve groups (n = 7 animals/group). Caﬀeic acid
(5 and 10mg/kg) and rosmarinic acid (5 and 10mg/kg)
were administered intraperitoneally, using saline as vehicle.
The control group were received saline (2mL/kg) by the
same route. For tail-ﬂick test animals were divided in three
groups (n = 10 animals/group) and rats were treated
intraperitoneally with 10mg/kg caﬀeic acid or rosmarinic
acid. The control group animals received the same experi-
mental handling as those of the test groups except that the
drugtreatment wasreplacedwith appropriatevolumesofthe
dosing saline.
2.3. Pleurisy Induction. Rats anaesthetized with ethyl ether,
and injected intrapleurally with 0.1mL of a 1mg/mL solu-
tionofcarrageenan, asdescribedby Spector[27].Fourhours
later, the animals were sacriﬁced with ethyl ether and the
pleural cavities were exposed. The exudates were collected
and thecavitywas ﬂushed with 2mL ofphosphated-buﬀered
saline (PBS). The total leukocyte number in the pleural
exudate was counted in a Neubauer chamber. Slides of the
cellular exudate were also prepared and diﬀerential cell
counting was performed. In this experiment leukocytes
accumulation in the peripheral blood was also determined.
Rats were ﬁrst anaesthetised and blood samples were taken
from the tail before and after 4 hours of the carrageenan
injection for diﬀerential leukocyte counting.
2.4. Antinociception Recording. Nociception was assessed
with a tail-ﬂick apparatus (Insight EFF-300) [28]. Rats were
wrapped in a towel and placed on the apparatus, the light
source positioned below the tail was focused on a point
2-3cm rostral to the tip of the tail. Deﬂection of the tail
activated a photocell and automatically terminated the trial.
Normal response latencies were usually between 2.5 and 3.0
seconds, and a 10 seconds cutoﬀ was used to prevent tissue
damage. Tail-ﬂick latency represented the period of time
fromthebeginningofthetrialtothetaildeﬂection.Onday1,
subjects were familiarized with the tail-ﬂick apparatus. This
was done because it has been observed that novelty itself
can induce antinociception [29]. On day 2, animals were
submitted to the tail-ﬂick measurement.
2.5. Statistical Analysis. Data from pleurisy are expressed
as mean ± standard error (S.E.M.). Comparisons between
counting before and after pleurisy inductionwere performed
using paired Students t-test. ANOVA and Tukey test were
used to compare the treatment groups. Latency to tail-ﬂick
(nonparametric data) are expressed as median (interquartil
range) and were analyzed by a Mann-Whitney U-test
(independent samples) or by Wilcoxon Matched-Pairs Test
(related samples).
3.Results
3.1. Eﬀects of Caﬀeic and Rosmarinic Acids on Carrageenan-
Induced Pleurisy. Total number of leukocytes showed a
signiﬁcant increase in both groups (treated and control) in
Table 1. The leukocytes recruited to the peripheral circu-
lation, which is primarily indicated by the increase in the
number of neutrophils after the induction of inﬂammation.
The analysis of cells in the pleural exudates revealed a
reduction of 66% of the number of leukocytes that migrated
to the pleural cavity in the animals treated with 5mg/kg
caﬀeic acid, and of 92.9% for the animals treated with
10mg/kg in comparison with the control group. These exu-
dates showed a balanced distribution of polymorphonuclear
(PMN) and mononuclear (MN) cells, as shown in Table 2,
diﬀerently from the control group, in which PMN cells were
predominant.
The administration of 5 and 10mg/kg produced marked
increases in total leukocytecountsafter inﬂammation induc-
tion. However, only the animals treated with 10mg/kg
showed a signiﬁcantly greater number of neutrophils than
the animals in the control group, both before and after
the administration of carrageenan (Table 1), as well as a
signiﬁcant increase in the number of lymphocytes afterISRN Pharmacology 3















n = 7 7350 ±3127.9 11175 ±1607.4
∗ 1183.75± 519.5 4779.83 ±1664.9
∗∗ 5826.75 ±2512 5401.3 ±917.73
RA (5mg/kg)
n = 7 7875 ±2332.76 12850 ±2202.95
∗∗ 1743.25± 833.16 6013.6 ±1548.85
∗∗ 5818.75 ±1960 6054.42 ±1816.62
RA (10mg/kg)
n = 7 8800 ±1945.5 14808.33±1120.45
∗∗A 2057.42 ±769.85B 7007.17±994.97
∗∗B 6274.42 ±2267.66 7270.25±1297.25B
CA (5mg/kg)
n = 7 9100 ±1801.4 14075 ±1553.57
∗∗A 1530.56± 1023.2 6659.81 ±2044.2
∗∗ 6890.5 ±1582.5 6307.63± 1478
CA (10mg/kg)
n = 7 7625 ±1906.24 12658.33±3598.95
∗∗A 820.58± 387.23 4758.25±2337.54
∗∗ 6479.3 ±1746.42 7387.58 ±1615.63
Mean ± standard error (SEM). Studentst-test:Compared withcontrol group AP<. 05, BP<. 01.Compared betweenbefore andafterinﬂammatoryinduction
process ∗P<. 05, ∗∗P<. 01.
pleurisy induction in comparison with the control group.
The analysis of cells that migrated to the pleural exudate
revealed a signiﬁcant reduction in leukocyte recruitment in
comparison with thecontrol group,with inhibition of78.2%
and 80.7% for animals treated with 5 and 10mg/kg. No
predominance ofPMN orMN cellswas found in the exudate
(Table 2).
The comparison of eﬀects of the treatment with ros-
marinic acid or caﬀeic acid on the inhibition of leukocyte
migration to the inﬂammation sites revealed a signiﬁcant
diﬀerence in the group of animals treated with 10mg/kg
caﬀeic acid in comparison with the other groups. There was
a reduction of 79.2% in the number of total exudate cells in
the group that received 5mg/kg caﬀeic acid, and of 67.6%
and 63.3% in the group treated with 5 and 10mg/kg of
rosmarinic acid.
3.2. Eﬀects of Rosmarinic and Caﬀeic Acids on Tail-Flick.
Figure 1 shows a signiﬁcant diﬀerence in the group of
animals treated with 10mg/kg caﬀeic acid in comparison
withtheothergroups.Theanalysisrevelatedahighlatencyto
tail-ﬂick characterizing a nociceptive response. There was no
diﬀerence between control group and animals treated with
rosmarinic.
4.Discussion
The intrapleural administration of carrageenan into the
pleural space leads to pleurisy, an inﬂammatory process
characterized by an immediate recruitment of polymor-
phonuclear cells (PMN). Carrageenan is a high-molecular-
weight sulphated polysaccharide, capable of inducing the
release of mediators involved in vascular changes associated
with acute inﬂammation [30]. The inﬂammation in the
respiratory pathway induces histamine, thromboxane A2,
leukotrienes, cytokines, and nitric oxide release [31].
Rosmarinic acid is a natural phenolic compound con-
tained in many Lamiaceae herbs. The medicinal value of this
substance has been well recognized, especially in regard to




























Control RA (10mg kg−1)C A ( 1 0 m g k g −1)
∗
Figure 1: Eﬀect of caﬀeic acid (CA) and rosmarinic acid (RA) on
the tail-ﬂick test in rats. Data expressed as median (interquartiles
range) of the tail-ﬂick latencies (n = 10 animal/group). Mann-
Whitney U-test: ∗P<. 05 compared with control group.
[20]observedthatrosmarinicacidinhibitedpathophysiolog-
icalchanges such as neutrophilicinﬂammation andedemain
the lung, in mice treated with administration of rosmarinic
acid (2mg/body for 3 days). These results suggested that ros-
marinic acid inhibits diesel exhaust particles (DEPs) induced
lung injury by the reduction of proinﬂammatory molecule
expression. These eﬀects were associated with the changes in
proinﬂammatory cytokineand chemokineexpression, which
play a crucial role in the initiation and progression of the
inﬂammatory response. Chemokines are a superfamily of
small, structurally related chemotactic cytokines involved in
leukocyte traﬃcking and activation [32].
Others studies on its anti-inﬂammatory activities led
to its discovery as an inhibitor of complement [33]. It
has been shown to inhibit both the classical and the
alternative pathways of complement activation [34, 35]a n d
complementdependentstimulation ofprostacyclinsynthesis
[36]. In vivo it is known to inhibit cobra venom factor-
induced paw edema [33, 34].4 ISRN Pharmacology
Table 2: Migrated leucocytes into pleural exudate in rats treated with caﬀeic acid (CA) and rosmarinicacid (RA).




1.56 ±0.64 1.12 ±0.57 0.44 ±0.22
RA (5mgkg−1)
n = 6
0.34 ±0.35A 0.18 ±0.14A 0.16 ± 0.13B
RA (10mgkg−1)
n = 6
0.30 ±0.15A 0.18 ±0.10A 0.12 ±0.08A
CA (5mgkg−1)
n = 8
0.53 ±0.17A 0.25 ±0.12A 0.28 ±0.18
CA (10mgkg−1)
n = 6
0.11 ±0.008A1 0.005 ± 0.003A1 0.006 ±0.003A1
Values are Mean ± S E M. PMN: polymorphonuclear cells. MN: mononuclear cells.
Student’s t-test: Compared with control group: AP<. 05, BP<. 01.
ANOVA/Tukey: Compared between groups: 1P<. 05.
Caﬀeic acid (3,4-dihydroxycinnamic acid) is one of the
natural phenolic compounds widely distributed in plant
m a t e r i a l ss u c ha sv e g e t a b l e s ,f r u i t s ,c o ﬀee, and tea [36].
This substance as an antioxidant can scavenge a number
of reactive species, including 1,1-diphenyl-2-picryl-hydrazyl
free radical (DPPH) [25, 26], peroxyl [23], and hydroxyl
radicals [24] as well as superoxide anion, peroxynitrite, and
mutageniccompoundssuch as nitrosamines [24, 26]. Caﬀeic
acid also inhibits 5-lipoxygenase (5-LOX) activity [21], and
inhibits protein kinase C (PKC), PKA and nuclear factor-κB
(NF-κB) activation induced by ceramides in U937 cells [22].
Others studies have been also reported to have antitumor
activity [37, 38], anti-inﬂammatory properties [39], and
anti-HIV replication activity [40].
Inthepresentstudy,weconﬁrmedtheanti-inﬂammatory
ability of caﬀeic and rosmarinic acids in animal model.
Experimental evidences obtained in the present study indi-
cated that caﬀeic acid and rosmarinic acid were able to
reduce polymorphonuclear and mononuclear cells migra-
tion into pleural space, 4 hours after pleurisy induction by
carrageenan. We also observed that animals treated with
10mg/kgcaﬀeicacidproducedan analgesiceﬀect30minutes
after drug administration on tail-ﬂick model. Our results
are in agreement with those reported by Shin et al. 2004
[41] where animals treated with caﬀeic acid at some dose,
signiﬁcantly increased the latency of the jumping response,
and the animals were not able to detect pain by hot plate
test.
Otherstudiesinvestigatingthepharmacologicalproﬁleof
these compounds showed that rosmarinic acid may present
an anxiolytic-like activity when used in low doses, without
aﬀecting the locomotion, exploration, and motivation [42].
In this work an intermediary doses were chosen based on the
literature [42]. The fact that caﬀeic acid produced analgesic
eﬀect in the nociceptive model is indicative that it had both
central and periferic antinociception and the mechanism
of action could be partially related to lipoxygenase and/or
cyclooxygenaseofthearachidonicacidcascadeand/oropioid
receptors [43, 44]. Analgesic eﬀect reﬂected in tail-ﬂick
tests is dependent on centrally action opioid-like analgesics
[44, 45]. Taken together, our results obtained in the tail-ﬂick
model corroborated that caﬀeic acid had central analgesic
activity, possibly by crossing the blood-brain barrier.
In our study, we observed the anti-inﬂammatory and
antinociceptive eﬀect was more pronounced in animals
treated with caﬀe i ca c i da sc o m p a r e dt ot h o s et r e a t e dw i t h
rosmarinic acid.German` oetal.[46]studiedratstreatedwith
nonhydrolyzedextractofTrichilia emetica Vahlandtheywere
detected in plasma levels of caﬀeic acid at 15 and 30 minutes
after, and they suggested its greater absorption in vivo by
intestinal cells. Baba et al. [47]s t u d y i n gr o s m a r i n i ca c i d
bioavailability in orally treated rats, veriﬁed maximal serum
concentration of this substance 1 hour after administration.
Rosmarinic acid was immediately metabolized, and one of
i t sm e t a b o l i t e si sc a ﬀeic acid. Therefore, we suggest that
the anti-inﬂammatory eﬀect observed in rats treated with
rosmarinic acid, is probably due to its breakdown products,
such as caﬀeic acid, as the highest inhibition of leukocyte
migration to the primary site of inﬂammation was obtained
with caﬀeic acid at 10mg/kg.
In conclusion, the results of the present study provide
further evidences of the anti-inﬂammatory and analgesic
properties of these phenolics compounds, which therefore
have potential applications in pain and inﬂammatory dis-
eases, with caﬀeic acid presenting the most potent anti-
inﬂammatory and antinociceptive eﬀects in these animal
models. However, further studies are needed to establish the
mechanism of the observed actions.
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